ArticleCurrent oncology (Toronto, Ont.)2023

Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer.

Beatrice T B Preti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.